Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resistance force for intraocular lens insertion through lens cartridges and syringe-type injectors.

Journal of cataract and refractive surgery·2015
Same author

The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β.

The EMBO journal·2015
Same author

Cell adhesion and glistening formation in hybrid copolymer intraocular lenses.

Ophthalmic research·2012
Same author

Successful closure of large blunt macular chorioretinal rupture: a case report.

Clinical ophthalmology (Auckland, N.Z.)·2012
Same author

[Terminal care for one-person household].

Gan to kagaku ryoho. Cancer & chemotherapy·2010
Same author

Adhesive retention of sodium hyaluronate ophthalmic viscosurgical devices in an acrylic tube model and in porcine-eye corneal endothelium with different irrigation rates.

Journal of cataract and refractive surgery·2009

Related Experiment Video

Updated: Jul 15, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

[Translational research with experimental autoimmune uveoretinitis (EAU)].

Masahiko Usui1

  • 1Department of Ophthalmology, Tokyo Medical University.

Nippon Ganka Gakkai Zasshi
|April 4, 2007
PubMed
Summary

Experimental autoimmune uveoretinitis (EAU) is a valid model for Behçet's disease uveitis. Therapies targeting immunosuppression, Th1 lymphocytes, and immunoregulatory cells show promise for treating ocular inflammation.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

Related Experiment Videos

Last Updated: Jul 15, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

Area of Science:

  • Ophthalmology
  • Immunology
  • Translational Medicine

Background:

  • Experimental autoimmune uveoretinitis (EAU) serves as a key animal model for human uveitis, particularly ocular inflammation in Behçet's disease.
  • EAU shares similarities with Behçet's disease, including anti-retinal antibodies, leukocyte migration inhibition, immunogenic antigens, neutrophil dysfunction, and Th1 lymphocyte responses.
  • EAU is a suitable model for translational research due to its focus on ocular inflammation without systemic Behçet's disease complications.

Purpose of the Study:

  • To evaluate therapeutic strategies for uveitis in Behçet's disease using the EAU model.
  • To investigate the efficacy of intraocular immunosuppression, Th1 lymphocyte inhibition, and immunoregulatory cell activation.
  • To assess the translational potential of EAU-based therapies for intraocular inflammation.

Main Methods:

  • Therapeutic strategies included intraocular tacrolimus (FK 506) administration, Th1 cell differentiation inhibition (anti-IL-12 mAb, anti-B7RP-1 mAb), and immunoregulatory cell activation (VIP/CGRP-treated APCs, CD4+CD25+ Tregs).
  • EAU was induced by immunization with retinal antigen (interphotoreceptor retinoid-binding protein; IRBP).
  • Tacrolimus efficacy and retinal safety were assessed. Th1 inhibition strategies involved blocking cytokine signaling and co-stimulatory pathways. Immunoregulatory cell therapies involved adoptive transfer.

Main Results:

  • Intravitreal tacrolimus (10 microg) effectively suppressed EAU in rats without retinal toxicity.
  • Anti-IL-12 mAb completely inhibited EAU development, while anti-B7RP-1 mAb suppressed EAU severity even after onset.
  • Adoptive transfer of treated antigen-presenting cells or regulatory T cells suppressed EAU.

Conclusions:

  • The EAU model is validated for translational research in ocular inflammation, specifically for Behçet's disease.
  • Targeting immunosuppression, Th1 lymphocyte pathways, and immunoregulatory cells demonstrates significant therapeutic potential for uveitis.
  • These findings support the development of novel therapies for intraocular inflammation based on EAU research.